HDAC9 and peripheral T-cell lymphoma, not otherwise specified: In clinical studies several classes of HDAC inhibitors demonstrated potent anticancer activities with remarkable tumor specificity, such as cutaneous T-cell lymphoma and peripheral T-cell lymphoma [26,27,28,29].